Chemical and pharmacological aspects of heteroaryl-nitrones
Identifieur interne : 003C05 ( Main/Exploration ); précédent : 003C04; suivant : 003C06Chemical and pharmacological aspects of heteroaryl-nitrones
Auteurs : Solo Goldstein [France] ; Pierre Lestage [France]Source :
- Current medicinal chemistry [ 0929-8673 ] ; 2000.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antioxidant, Aromatic compound, Benzene derivatives, Chemical synthesis, Furan derivatives, Imidazole derivatives, Nitrogen Oxides (chemistry), Nitrogen Oxides (pharmacology), Nitrogen heterocycle, Nitrone, Oxygen heterocycle, Pyridine derivatives, Radical scavenger, Research and development, Review, Thiophene derivatives.
- MESH :
- chemical , chemistry : Nitrogen Oxides.
- chemical , pharmacology : Nitrogen Oxides.
Abstract
Radical induced oxidative damage is extremely harmful to tissues and organs due to molecular modifications brought to polyunsaturated membrane lipids, proteins and nucleic acids. Oxidative stress is believed to be one of the pathophysiological mechanisms that operate in neurodegenerative disorders such as cerebral ischemias, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's diseases. Nitrones oppose oxidative challenges by virtue of their ability to trap very rapidly oxygen or carbon centered radicals thus generating nitroxide radical species which are more stable and biochemically less harmful than the original radical. However the operational mechanism of nitrones might also go beyond direct scavenging of radicals. The chemical and pharmacological properties of nitrones depend strongly on the connectivity as well as on the type and position of the substituents in the compound's architecture. Heteroaryl-nitrones are known, but except for a few cases (for example pyridyl-nitrones) no particular attention has been given to this class of molecules. The following review is a survey of the literature reports on this subject from 1980 to 1999. The structures were classified according to the heterocyclic substituent on the nitrone double bond, and documented pharmaceutical features were emphasized. Whenever possible heteroaromatic and related aromatic nitrones were compared.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001293
- to stream PascalFrancis, to step Curation: 000145
- to stream PascalFrancis, to step Checkpoint: 001236
- to stream Main, to step Merge: 004273
- to stream PubMed, to step Corpus: 001282
- to stream PubMed, to step Curation: 001241
- to stream PubMed, to step Checkpoint: 001241
- to stream Ncbi, to step Merge: 000142
- to stream Ncbi, to step Curation: 000142
- to stream Ncbi, to step Checkpoint: 000142
- to stream Main, to step Merge: 003F28
- to stream Main, to step Curation: 003C05
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Chemical and pharmacological aspects of heteroaryl-nitrones</title>
<author><name sortKey="Goldstein, Solo" sort="Goldstein, Solo" uniqKey="Goldstein S" first="Solo" last="Goldstein">Solo Goldstein</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institut de Recherches Servier Chemistry Research Division A, 11 rue des Moulineaux</s1>
<s2>92150 Suresnes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Suresnes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lestage, Pierre" sort="Lestage, Pierre" uniqKey="Lestage P" first="Pierre" last="Lestage">Pierre Lestage</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Cerebral Pathology, 125 Chemin de Ronde</s1>
<s2>78290 Croissy sur Seine</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Croissy sur Seine</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0009153</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 01-0009153 INIST</idno>
<idno type="RBID">Pascal:01-0009153</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001293</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000145</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001236</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001236</idno>
<idno type="wicri:doubleKey">0929-8673:2000:Goldstein S:chemical:and:pharmacological</idno>
<idno type="wicri:Area/Main/Merge">004273</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11032970</idno>
<idno type="wicri:Area/PubMed/Corpus">001282</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001282</idno>
<idno type="wicri:Area/PubMed/Curation">001241</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001241</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001241</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001241</idno>
<idno type="wicri:Area/Ncbi/Merge">000142</idno>
<idno type="wicri:Area/Ncbi/Curation">000142</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000142</idno>
<idno type="wicri:doubleKey">0929-8673:2000:Goldstein S:chemical:and:pharmacological</idno>
<idno type="wicri:Area/Main/Merge">003F28</idno>
<idno type="wicri:Area/Main/Curation">003C05</idno>
<idno type="wicri:Area/Main/Exploration">003C05</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Chemical and pharmacological aspects of heteroaryl-nitrones</title>
<author><name sortKey="Goldstein, Solo" sort="Goldstein, Solo" uniqKey="Goldstein S" first="Solo" last="Goldstein">Solo Goldstein</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institut de Recherches Servier Chemistry Research Division A, 11 rue des Moulineaux</s1>
<s2>92150 Suresnes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Suresnes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lestage, Pierre" sort="Lestage, Pierre" uniqKey="Lestage P" first="Pierre" last="Lestage">Pierre Lestage</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Cerebral Pathology, 125 Chemin de Ronde</s1>
<s2>78290 Croissy sur Seine</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Croissy sur Seine</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antioxidant</term>
<term>Aromatic compound</term>
<term>Benzene derivatives</term>
<term>Chemical synthesis</term>
<term>Furan derivatives</term>
<term>Imidazole derivatives</term>
<term>Nitrogen Oxides (chemistry)</term>
<term>Nitrogen Oxides (pharmacology)</term>
<term>Nitrogen heterocycle</term>
<term>Nitrone</term>
<term>Oxygen heterocycle</term>
<term>Pyridine derivatives</term>
<term>Radical scavenger</term>
<term>Research and development</term>
<term>Review</term>
<term>Thiophene derivatives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Nitrogen Oxides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Nitrogen Oxides</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Article synthèse</term>
<term>Recherche développement</term>
<term>Antioxydant</term>
<term>Intercepteur radical</term>
<term>Nitrone</term>
<term>Composé aromatique</term>
<term>Benzène dérivé</term>
<term>Hétérocycle azote</term>
<term>Hétérocycle oxygène</term>
<term>Imidazole dérivé</term>
<term>Synthèse chimique</term>
<term>Pyridine dérivé</term>
<term>Furane dérivé</term>
<term>Thiophène dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Radical induced oxidative damage is extremely harmful to tissues and organs due to molecular modifications brought to polyunsaturated membrane lipids, proteins and nucleic acids. Oxidative stress is believed to be one of the pathophysiological mechanisms that operate in neurodegenerative disorders such as cerebral ischemias, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's diseases. Nitrones oppose oxidative challenges by virtue of their ability to trap very rapidly oxygen or carbon centered radicals thus generating nitroxide radical species which are more stable and biochemically less harmful than the original radical. However the operational mechanism of nitrones might also go beyond direct scavenging of radicals. The chemical and pharmacological properties of nitrones depend strongly on the connectivity as well as on the type and position of the substituents in the compound's architecture. Heteroaryl-nitrones are known, but except for a few cases (for example pyridyl-nitrones) no particular attention has been given to this class of molecules. The following review is a survey of the literature reports on this subject from 1980 to 1999. The structures were classified according to the heterocyclic substituent on the nitrone double bond, and documented pharmaceutical features were emphasized. Whenever possible heteroaromatic and related aromatic nitrones were compared.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Croissy sur Seine</li>
<li>Suresnes</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Goldstein, Solo" sort="Goldstein, Solo" uniqKey="Goldstein S" first="Solo" last="Goldstein">Solo Goldstein</name>
</region>
<name sortKey="Lestage, Pierre" sort="Lestage, Pierre" uniqKey="Lestage P" first="Pierre" last="Lestage">Pierre Lestage</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Exploration |type= RBID |clé= Pascal:01-0009153 |texte= Chemical and pharmacological aspects of heteroaryl-nitrones }}
This area was generated with Dilib version V0.6.29. |